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Abstract 
Background: Many patients develop tumour recurrence within a few years after undergoing surgical resection of 
gastrointestinal stromal tumours (GIST). Adjuvant imatinib treatment is recommended for patients with high risk of 
GIST recurrence as it can improve recurrence-free survival and overall survival of patients. This study aims to assess the 
cost-utility of adjuvant imatinib in patients with high risk of GIST recurrence after surgery compared with no adjuvant 
therapy in Thailand.
Methods: A Markov model was developed to estimate lifetime costs and outcomes of using adjuvant imatinib treat-
ment and other treatment alternatives if recurrence occurred compared with the current situation of no adjuvant 
therapy in high-risk patients after surgery. A 1-month cycle length was deployed in the model. Transition probabilities 
were derived from literature review. Costs were collected and calculated for the year 2014 from a societal perspec-
tive. Future costs and outcomes were discounted at 3% per year. One-way and probabilistic sensitivity analyses were 
conducted to assess parameter uncertainties.
Results: Three years of adjuvant imatinib treatment followed by imatinib treatment and best supportive care if 
recurrence occurred after or during adjuvant therapy, respectively, was the best option as it produced more health 
outcomes (1.23 life years (LYs) and 1.16 quality-adjusted life years (QALYs)) compared to no adjuvant therapy while 
yielding the lowest incremental cost-effectiveness ratio (ICER) of 1,648,801 Thai Baht (THB) per QALY gained. Three 
years of adjuvant imatinib treatment followed by sunitinib treatment if recurrence occurred had an ICER of 2,608,264 
THB per QALY gained compared to the best option, while other options were dominated. A one-way sensitivity analy-
sis showed that the utility of patients receiving adjuvant imatinib had the greatest effect on the model, followed by 
the discount rate and probability of GIST recurrence.
Conclusions: Adjuvant imatinib treatment improved the health benefits of patients with high risk of GIST recurrence. 
However, in the Thai context, it was not cost-effective at the current price.
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Background
Gastrointestinal stromal tumours (GIST) are the most 
common mesenchymal tumours of the gastrointestinal 
(GI) tract [1]. GIST can be found in any part of the GI 
tract but mostly occur in the stomach and small intes-
tine. Most cases of GIST are associated with mutations 
in either KIT or PDGFRA (platelet-derived growth factor 
receptor alpha). The activation of those mutations leads 
to the end result of an increase in cellular proliferation 
and a decrease in apoptosis [1–3]. GIST can be diag-
nosed by histological examinations, CD117 (c-kit) immu-
nohistochemistry, and other imaging techniques such as 
computed tomography (CT), magnetic resonance imag-
ing (MRI), upper GI endoscopy, and fluorine-18-fluoro-
deoxyglucose positron emission tomography (FDG-PET). 
The clinical presentation of GIST can be asymptomatic 
or symptomatic; common symptoms of GIST include 
abdominal pain, and GI bleeding and obstruction [2, 4].
The standard treatment for localized GIST is a com-
plete resection [4]; however, many patients have disease 
recurrence after surgery [5]. The evidence from a rand-
omized phase III, placebo-controlled, multicenter trial 
showed that 400 mg of tyrosine kinase inhibitor, imatinib 
mesylate per day for 1  year significantly improved 
recurrence-free survival (RFS) compared with the pla-
cebo (hazard ratio 0.35; 95% CI 0.22–0.53; p < 0.0001) in 
patients with complete resection of GIST greater than 
3  cm [6]. In addition, the results from another rand-
omized phase III study comparing the efficacy of 1 and 
3  years of adjuvant imatinib treatment in patients with 
high risk of GIST recurrence after surgery indicated that 
extending the duration of adjuvant imatinib treatment to 
3 years could improve both RFS (hazard ratio 0.46; 95% 
CI 0.32–0.65; p < 0.001) and overall survival (hazard ratio 
0.45; 95% CI 0.22–0.89; p = 0.02) compared to just 1 year 
of adjuvant imatinib treatment [7].
According to the benefits of adjuvant imatinib treat-
ment based on available evidence, some agencies rec-
ommend adjuvant imatinib therapy. For example, the 
National Comprehensive Cancer Network (NCCN) in the 
United States recommends adjuvant imatinib treatment 
after resection for primary GIST for at least 12 months in 
intermediate- to high-risk patients [8], whereas the Euro-
pean Society for Medical Oncology (ESMO) in Europe 
recommends adjuvant therapy for 3 years only in patients 
with high risk of recurrence (it is not recommended for 
patients with low risk of recurrence) [9]. There are sev-
eral risk stratification schemes available to determine 
the risk of GIST recurrence after surgery such as the 
National Institutes of Health (NIH) consensus crite-
ria, Armed Forces Institute of Pathology (AFIP) criteria, 
and Modified NIH criteria. Many prognostic factors are 
considered including tumour size, mitosis count, tumour 
site, and tumour rupture, depending on the criteria of 
each scheme [9, 10]. However, experts in Thailand nor-
mally estimate the risk of GIST recurrence based on the 
Modified NIH criteria. This scheme takes all four of those 
previously mentioned factors into consideration, whereas 
the NIH consensus criteria focus only on tumour size 
and mitosis count. Patients with a large tumour and/or 
frequent mitoses have a high risk of recurrence. Non-gas-
tric sites also increase the risk of recurrence, according to 
the Modified NIH criteria. Additionally, tumour rupture 
also leads to a high risk of recurrence regardless of sizes, 
sites, and mitosis count [10]. There is no report on the 
incidence and prevalence of GIST in Thailand. However, 
experts estimate that the new cases of GIST patients who 
undergo resections and have a high risk of recurrence are 
approximately 100 persons per year in Thailand.
In Thailand, 400 mg of imatinib per day is included in 
the National List of Essential Medicines (NLEM) only for 
the treatment of patients with unresectable and/or met-
astatic GIST, whereas adjuvant imatinib treatment for 
patients with high risk of GIST recurrence after surgery 
has not yet been included. An economic evaluation is 
needed to inform the Subcommittee for the Development 
of the NLEM about the cost-effectiveness of this new 
indication of imatinib treatment to determine whether 
to include it into the NLEM or not. Therefore, this study 
aims to assess the cost-utility of adjuvant imatinib ther-
apy in patients with high risk of GIST recurrence after 
surgery compared with no adjuvant therapy in Thailand.
Methods
A Markov model was developed to estimate the costs and 
health outcomes based on a societal perspective of using 
adjuvant imatinib treatment and drug treatment alterna-
tives if recurrence occurred, compared with the current 
situation of no adjuvant therapy. The study population 
was primary localized GIST patients who underwent 
complete resections and had a high risk of recurrence 
as determined by the Modified NIH criteria. A lifetime 
horizon was performed with a 1-month cycle length in 
the model. As the time horizon of this study was more 
than 1 year, future costs and outcomes were discounted 
at 3% per year.
According to national and international practice guide-
lines—as well as being in line with the criteria of using 
imatinib in the Thai NLEM that allows for the use of 
400  mg of imatinib per day only for metastatic GIST—
this study focused on four alternative treatment options 
varying in accordance with adjuvant treatment and 
treatment after disease recurrence and progression. The 
details of each option are described (Table 1) as follows:
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Option 1  No adjuvant imatinib therapy after surgery 
was given. If disease recurrence occurred, 
patients received 400 mg of imatinib per day. 
If the disease continued to progress, patients 
stopped imatinib treatment and received 
best supportive care (baseline case).
Option 2  400  mg of adjuvant imatinib per day after 
surgery was given for 1 year (option 2.1) or 
3 years (option 2.2).
• 2.1: If disease recurrence occurred during adjuvant 
therapy, patients stopped adjuvant imatinib treat-
ment and received best supportive care.
• 2.2: If disease recurrence occurred after adjuvant 
therapy had been completed, patients received 
400 mg of imatinib per day. If the disease continued 
to progress, patients stopped imatinib treatment and 
received best supportive care.
Option 3  400  mg of adjuvant imatinib per day after 
surgery was given for 1 year (option 3.1) or 
3 years (option 3.2) .
• 3.1: If disease recurrence occurred during adjuvant 
therapy, patients stopped adjuvant imatinib treat-
ment and received a treatment of 50 mg of sunitinib 
per day. If the disease continued to progress, patients 
received best supportive care instead of the sunitinib 
treatment.
• 3.2: If disease recurrence occurred after adjuvant 
therapy had been completed, patients received 
400 mg of imatinib per day. If the disease continued 
to progress, patients stopped the imatinib treatment 
and received a treatment of 50  mg of sunitinib per 
day. If the disease still continued to progress, patients 
received best supportive care instead of the sunitinib 
treatment.
Option 4  no adjuvant imatinib therapy after surgery 
was given. If disease recurrence occurred, 
patients received 400  mg of imatinib per 
day. If the disease continued to progress, 
patients stopped imatinib treatment and 
received a treatment of 50  mg of sunitinib 
per day. If the disease still continued to pro-
gress, patients received best supportive care 
instead of the sunitinib treatment.
Model structure
The Markov model can be seen as illustrated in Fig.  1. 
There were three health states: (1) patients with no 
GIST recurrence; (2) patients with GIST recurrence; 
and (3) death from GIST and other causes. Four models 
were developed and based on the alternative treatment 
options.
The models started with patients aged 60 years old with 
no GIST recurrence after surgery. For options 1 and 4, 
no adjuvant imatinib therapy was applied. Patients with 
no disease recurrence could remain at the same state 
or move either to the recurrence state or death state. 
After patients entered the recurrence state (grey color), 
the states transitioned in accordance with each treat-
ment option. For options 2 and 3, adjuvant imatinib 
was applied for 1 year or 3 years. Patients with adjuvant 
imatinib could either stop adjuvant treatment due to 
adverse events caused by the treatment or complete the 
treatment course. If recurrence occurred (grey color) 
after completing or during the adjuvant treatment, the 
states transitioned according to treatment options—simi-
lar to options 1 and 4.
For all health states, patients could remain in the same 
state or transition to the death state. The model assumed 
that recurrence was metastatic and not local as the litera-
ture showed that the proportion of metastatic recurrence 
after completed resections was higher [5].
Table 1 Alternative treatment options
BSC best supportive care











Imatinib (recurrence occurred after adjuvant therapy completed) BSC





Imatinib (recurrence occurred after adjuvant therapy completed) Sunitinib
Sunitinib (recurrence occurred during adjuvant therapy) BSC
Option 4 No Imatinib Sunitinib
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Clinical variables
Transitional probabilities of recurrence and death in 
patients with no adjuvant imatinib treatment were 
obtained from a retrospective chart review (Sarunporn 
Techasurungkul, Faculty of Medicine, Ramathibodi 
Hospital, Mahidol University, personal communication, 
November 20, 2014). A systematic review of randomized 
controlled trials (RCTs) published until 2014 was con-
ducted to search for the hazard ratio of disease recur-
rence in patients receiving adjuvant imatinib treatment 
Fig. 1 Markov model structure
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compared with no adjuvant imatinib treatment after 
surgery. Two studies were identified from the review: 
Joensuu et  al. [7] investigated the efficacy of adjuvant 
imatinib treatment for 3  years compared with 1  year of 
adjuvant imatinib treatment in GIST patients with high 
risk of recurrence, while DeMatteo et  al. [6] compared 
1  year of adjuvant imatinib treatment with no adjuvant 
therapy. However, there was no study which compared 
3 years of adjuvant imatinib treatment with no adjuvant 
therapy, and thus an indirect comparison analysis was 
performed from those two studies by using the ITC pro-
gramme developed by the Canadian Agency for Drugs 
and Technologies in Health (CADTH) [11]. The values of 
the parameters are shown in Table 2.
Since it was not clear that overall survival improved 
because of the adjuvant imatinib treatment, the improved 
duration of survival may have been due to treatments 
given after recurrence. Therefore, this study assumed that 
the probability of death during no recurrence was the 
same regardless of adjuvant therapy received. The prob-
ability of adjuvant therapy discontinuation was derived 
from literature review, and the probability of recurrence 
in this group was equal to patients with no adjuvant 
therapy. After recurrence, the transitional probabilities—
including the probabilities of disease progression and 
death during the given treatment—were derived from a 
study by Mohara [12]. Additionally, mortality rates of the 
Thai population at each age were applied [13].
The model validation was performed by comparing 
survival estimation from the model and from an inter-
national RCT [7] as shown in Fig. 2. We found that our 
estimation provided similar results in terms of patient 
survival in the first 3 years. However, the model predicted 
a slightly higher mortality in the 4th and 5th year com-
pared to that of RCT. It was because this study assumed, 
based on an agreement with local expert panel, that the 
treatment effect would be observed when patients were 
taking the medicine. This point is debatable, because 
there is no clear evidence in the current literature. Our 
findings, nonetheless, were acceptable to stakeholders 
in the consultation meeting conducted towards the end 
of the project, which was also a part of the model vali-
dation process. They indicated that this mortality esti-
mation was representative of the real-world situation in 
Thailand.
Costs
Direct medical and non-medical costs were included 
based on the societal perspective. Direct medical costs 
included the cost of drugs, cost of treating and monitor-
ing, and cost of adverse event treatment. The reference 
prices of drugs were obtained from the Drug and Medical 
Supply Information Center (DMSIC), Ministry of Public 
Health. 400 mg of imatinib and 12.5 mg of sunitinib cost 
3,659.40 Thai Baht (THB) per tablet and 1100.53 THB 
per capsule in 2014, respectively [14].
Resources used for treating and monitoring patients 
during no recurrence were collected from a review of 
medical charts in Songklanagarind Hospital during 
2009–2014. Those were mostly from outpatient care, 
e.g. radiology services, laboratory services, outpatient 
services, and other drugs. Resources used for treating 
the adverse events caused by adjuvant imatinib treat-
ment were obtained from expert opinion based on the 
adverse events that occurred from literature review [7]. 
Subsequently, costs were calculated according to those 
resources used and reference costs from the Thai stand-
ard costs list [15]. Moreover, direct non-medical costs 
such as the costs of travel, food, and opportunity cost of 
caregivers during no recurrence were estimated from the 
number of patients’ visits per month, obtained from a 
review of charts in Songklanagarind Hospital, and costs 
per visit were based on the Thai standard costs list.
Both direct medical and non-medical costs incurred 
during recurrence were retrieved from a Thai literature 
review [12]. All costs were adjusted to 2014 values by 
using the consumer price index (CPI).
Health outcomes
Health outcomes in this study were life years (LYs) 
gained and quality-adjusted life years (QALYs) gained 
(multiplication of utility value and life years). The qual-
ity of life scores were collected by using the EQ-5D-3L 
questionnaire to interview 23 patients with high risk of 
GIST recurrence after surgery (5 patients who received 
adjuvant imatinib treatment and 18 patients who did 
not receive adjuvant imatinib treatment) at Ramathibodi 
and Songklanagarind Hospitals. To convert quality of life 
scores into utility values, Thai population coefficients 
were applied [16]. This study was approved by the Ethi-
cal Committees of Ramathibodi and Songklanagarind 
Hospitals.
Data analysis
The incremental cost-effectiveness ratio (ICER) in THB 
per QALY gained was analyzed. The ICER was compared 
with the willingness-to-pay (WTP) threshold to deter-
mine whether each option was cost-effectiveness or not. 
In Thailand, the Subcommittee for Development of the 
NLEM and the Subcommittee for Development of the 
Health Benefit Package and Service Delivery, National 
Health Security Office (NHSO), set the WTP threshold 
at 160,000 THB per QALY gained.
A one-way sensitivity analysis was conducted to exam-
ine the effect of each individual parameter uncertainty, 
and the results were presented in a tornado diagram. A 
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Table 2 Parameters used in the model
Parameters Distribution Mean SE References
Probability of recurrence in patients with no adjuvant imatinib treatment (per month)
 Probability of recurrence at year 1 Beta 0.0205 0.0041 Chart  reviewa
 Probability of recurrence at year 3 Beta 0.0154 0.0031
 Probability of recurrence at year 5 Beta 0.0056 0.0011
Probability of death from GIST in patients with no adjuvant imatinib treatment (per month)
 Probability of death at year 1 Beta 0.0017 0.0003 Chart  reviewa
 Probability of death at year 3 Beta 0.0031 0.0006
 Probability of death at year 5 Beta 0.0028 0.0006
 Probability of death at year 7 Beta 0.0020 0.0004
 Probability of death at year 9 Beta 0.0038 0.0008
Hazard ratio (HR) of recurrence in patients receiving adjuvant imatinib treatment (compared with no adjuvant imatinib treatment)
 Adjuvant imatinib treatment for 1 year Log normal 0.29 0.0995 [6]b
 Adjuvant imatinib treatment for 3 years Log normal 0.133 0.0543 Indirect comparison of [6] and [7]
Probability of progression during treatment (per month)
 Imatinib treatment Beta 0.015 0.0038 [12]
 Sunitinib treatment Beta 0.012 0.0010
Probability of death during treatment (per month)
 Imatinib treatment Beta 0.0056 0.0009 [12]
 Sunitinib treatment Beta 0.0289 0.0087
 Best supportive care Beta 0.0680 0.0093
Probability of discontinuation of adjuvant imatinib treatment (per month)
 Adjuvant imatinib treatment for 1 year (1–6 months) Beta 0.0136 0.0014 [17]
 Adjuvant imatinib treatment for 1 year (7–12 months) Beta 0.0009 0.0001
 Adjuvant imatinib treatment for 3 years (1–6 months) Beta 0.0097 0.0001
 Adjuvant imatinib treatment for 3 years (7 months onwards) Beta 0.0028 0.0003
Direct medical costs (THB per month)
 Imatinib 400 mg/day – 111,306 – [14]
 Sunitinib 50 mg/day (receive drug for 4 weeks, then stop for 2 weeks, and repeat a cycle) – 82,173 –
 Costs for patients with no recurrence and no adjuvant imatinib treatment Gamma 2758 308 Hospital database
 Costs for patients with no recurrence and receiving adjuvant imatinib  treatmentc Gamma 1477 573
 Costs for patients during recurrence and receiving imatinib  treatmentc Gamma 421 38 [12]
 Costs for patients during recurrence and receiving sunitinib  treatmentc Gamma 714 150
 Costs for patients during recurrence and receiving best supportive care Gamma 424 78
 Costs for treating adverse events from adjuvant imatinib treatment Gamma 570 114 Expert opinion
Direct non-medical costs
 Travel costs (THB per visit) Gamma 296 24 [15]
 Food costs (THB per visit) Gamma 109 11
 Opportunity cost of caregivers (THB per visit) Gamma 99 37
 Number of visits for patients with no recurrence and no adjuvant imatinib treatment 
(visits per month)
Gamma 0.3 0.1 Hospital database
 Number of visits for patients with no recurrence and receiving adjuvant imatinib treat-
ment (visits per month)
Gamma 0.6 0.2
 Number of visits for patients during recurrence (visits per month) – 1 – [12]
Utility
 No recurrence and no adjuvant imatinib treatment Beta 0.89 0.03 Interviewing patients
 No recurrence and receiving adjuvant imatinib treatment Beta 0.79 0.09
 Recurrence and receiving imatinib treatment Beta 0.66 0.05 [12]
 Recurrence and receiving sunitinib treatment Beta 0.58 0.06
 Recurrence and receiving best supportive care Beta 0.42 0.03
a  Sarunporn Techasurungkul, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, personal communication, November 20, 2014
b  The study population was patients with GIST of greater than 3 cm, so only a subgroup analysis of patients with GIST of greater than 10 cm was used to represent 
patients with high risk of recurrence
c Excluding drug costs (imatinib or sunitinib)
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probabilistic sensitivity analysis (PSA) was also carried 
out to explore the effect of all parameter uncertainties 
using a Monte Carlo simulation approach. The simula-
tion was run for 1000 times to yield the possible values 
for total costs, health outcomes, and ICER; these results 
are presented in cost-effectiveness acceptability curves. 
Additionally, if the current price of imatinib was found to 
be not cost-effective, a threshold sensitivity analysis was 
conducted to determine the price that would result in 




Table  3 shows the lifetime costs, outcomes, and ICER 
of alternative treatment options in GIST patients aged 
60 years old and above with high risk of recurrence after 
surgery. It was found that option 3.2 yielded the high-
est lifetime cost (5.1 million THB) and outcomes (8.17 
LYs and 6.65 QALYs). Meanwhile, option 1 had the low-
est cost (2.7 million THB) and outcomes (6.72 LYs and 
5.34 QALYs). All options were ranked in terms of cost 
—from the lowest to the highest—and the ICER of each 
option was calculated by comparing with that of the next 
option (e.g. option 4 comparing with option 1, option 
2.1 comparing with option 4, etc.). Option 4, 2.1 and 3.1 
were dominated by option 2.2 because they yielded less 
QALYs, but they resulted in a higher cost-effectiveness 
ratio compared to that of option 2.2. Therefore, option 
2.2—patients who received adjuvant imatinib treatment 
for 3  years and continued to receive imatinib treatment 
and best supportive care depending on whether recur-
rence occurred after or during adjuvant therapy, respec-
tively—was shown to be the best with the ICER of 1.6 
million THB per QALY gained when compared to the 
current option (option 1). Option 3.2 was the next best 
option with an ICER of 2.6 million THB per QALY 
gained compared to option 2.2. Figure 3 shows the incre-
mental cost and QALYs of each option comparing with 
the current option. The efficiency frontier was conducted 
by drawing a line between the better options where the 
slope between each option represented the ICER.
Uncertainty analysis
Figure 4 presents the one-way sensitivity analysis results 
of the best option (option 2.2) via a tornado diagram. 
These results showed the effect of varying each param-
eter within the 95% confidence interval (CI) on the ICER. 
The parameter that affected the ICER the most was the 
utility of patients with no recurrence and on adjuvant 
imatinib treatment, followed by discount rates of 0% and 
6% per annum and the probability of recurrence.
Fig. 2 Overall survival of patients receiving adjuvant imatinib after surgery obtaining from the model and from the RCT 
Page 8 of 12Bussabawalai et al. Cost Eff Resour Alloc            (2019) 17:1 
Figure  5 shows the PSA results, presented in cost-
effectiveness acceptability curves. The results illus-
trated the probability of each treatment option being 
cost-effective at various WTP thresholds. It was found 
that at the WTP threshold of 160,000 THB per QALY 
gained, the probability of the current option being 
cost-effective was 100%, whereas the probability of 
other treatment options being cost-effective was 0%.
A threshold analysis was conducted to find the cost-
effective price of providing adjuvant imatinib treat-
ment at the WTP of 160,000 THB per QALY gained. 
Based on the option most likely to be cost-effective 
(option 2.2), adjuvant imatinib treatment would 
be cost-effective in the Thai context if the price of 
imatinib decreased from 3659 THB per 400 mg to 288 
THB per 400 mg (a decrease of about 92%).
Table 3 Lifetime costs, outcomes, and ICERs of alternative treatment options





2,744,275 8.13 6.72 5.34 –
Option 4 3,368,809 8.57 7.05 5.58 Dominated by option 2.2
Option 2.1 3,393,388 8.56 7.01 5.63 Dominated by option 2.2
Option 3.1 3,979,869 8.97 7.33 5.86 Dominated by option 2.2
Option 2.2 4,648,080 9.87 7.95 6.50 1,648,801
Option 3.2 5,056,583 10.17 8.17 6.65 2,608,264
Fig. 3 Cost-effectiveness plane and efficiency frontier
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Discussion
Patients with high risk of GIST recurrence who received 
adjuvant imatinib treatment after surgery would gain 
higher QALYs and yield higher lifetime costs as well 
when compared to no adjuvant therapy. The 3-year adju-
vant imatinib treatment also produced higher QALYs and 
costs than 1  year of adjuvant imatinib treatment. Nev-
ertheless, at the Thai WTP threshold of 160,000 THB 
per QALY gained, adjuvant imatinib treatment was not 
cost-effective in those patients compared to the current 
practice. A 3-year adjuvant imatinib treatment followed 
by imatinib treatment and best supportive care if recur-
rence occurred after or during adjuvant therapy, respec-
tively, was the best option as it yielded the lowest ICER of 
1,648,801 THB per QALY gained. This treatment option 
would be cost-effective if the price of imatinib 400  mg 
decreased from 3659 THB to 288 THB.
Studies on the cost-effectiveness of adjuvant imatinib 
treatment in GIST patients after surgery have been con-
ducted in several countries. Two studies conducted in the 
Fig. 4 One-way sensitivity analysis
Page 10 of 12Bussabawalai et al. Cost Eff Resour Alloc            (2019) 17:1 
United States and Netherlands were published in interna-
tional journals [17, 18], while another three studies con-
ducted in Canada, Scotland, and Greece were presented 
at the Congress of the European Society for Medical 
Oncology in 2012 [19–21]. All of those studies aimed to 
compare the cost-effectiveness of adjuvant imatinib treat-
ment for 3  years with an adjuvant imatinib treatment 
for 1 year. Only the study conducted in Greece assessed 
other scenarios, in which one of those cost-effectiveness 
comparisons was between 3  years of adjuvant imatinib 
treatment versus no adjuvant therapy. The results of all 
the studies illustrated that adjuvant imatinib treatment 
for 3 years was cost-effective in their respective contexts 
when compared with either a 1 year of adjuvant imatinib 
treatment or no adjuvant therapy (only for the Greece 
study). The difference in conclusions between the other 
studies and this one was caused by differences in both 
interventions and comparators as this study assessed all 
treatment options based on the current clinical prac-
tice in Thailand. For example, the Greece study allowed 
patients to receive a high dose of imatinib before receiv-
ing sunitinib treatment when GIST recurrence occurred 
[20], but this study did not consider that treatment. This 
study was also the only one that compared treatment 
options after GIST recurrence, whereas other studies 
focused only on adjuvant imatinib treatment (treatment 
after GIST recurrence was the same between the 3-year 
and 1-year groups, and the proportion of patients receiv-
ing a particular treatment after GIST recurrence was 
based on expert opinion) [17, 18].
The sources of the parameters used in the model 
were also different, particularly for utility. Other stud-
ies derived the utilities of patients in each status from 
literature review or expert opinion; however, this study 
obtained them from interviewing Thai patients or from 
a Thai study that collected this data via interviews as 
well. Additionally, this study analyzed the results based 
on a societal perspective, whereas others used the payer’s 
or provider’s perspectives. On the other hand, similar 
to other studies, the results of this study indicated that 
Fig. 5 Cost-effectiveness acceptability curves
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3  years of adjuvant imatinib treatment provided better 
health outcomes in terms of both LYs and QALYs, and 
yielded higher costs compared with 1  year of adjuvant 
imatinib treatment.
Several limitations were encountered in this study. Due 
to the fact that there was no study on the effectiveness of 
adjuvant imatinib treatment in Thai patients, the hazard 
ratios of recurrence obtained from international clinical 
trials for patients who received adjuvant imatinib treat-
ment were applied with the probability of recurrence in 
Thai patients without adjuvant therapy in order to obtain 
the probability of recurrence in patients receiving adju-
vant imatinib treatment that reflects the Thai population. 
However, those hazard ratios were applied only dur-
ing the period that patients received adjuvant imatinib 
treatment, i.e. either for 1 or 3 years. This may, therefore, 
result in the underestimation of the effectiveness of adju-
vant imatinib treatment.
The probabilities of recurrence and death of GIST 
patients without adjuvant imatinib after surgery were 
derived from medical records review, which could be bias 
due to the potential confounding factors that could not 
be taken out based on the study design—i.e. retrospec-
tive cohort study. It may the case that the patients with-
out recurrence might not come back to see the doctors; 
hence, we might have overestimated the probability of 
recurrence due to the missing data from this group of 
patients. In contrast, the hospitals might not have medi-
cal records on patients who died at home, which could 
also lead us to underestimate the probability of dying. In 
summary, this limitation can both be positive and nega-
tive from the conclusion.
This study used two sources of data—i.e. primary 
data and secondary data, to obtain health utility of the 
patients. A primary data collection on health utility was 
conducted in 23 patients for only a health state of patients 
without GIST recurrence. Meanwhile, health utility 
of patients with GIST recurrence were obtained from 
another Thai study conducted by Mohara [12] which 
interviewed other 22 patients. This study employed data 
on health utilities from another Thai study rather than 
conducting primary data collection for all health states, 
because the target population in Mohara’s study and this 
study were the same –i.e. Thai patients with GIST. Moha-
ra’s study obtained health utilities from patients with 
GIST recurrence using the same utility measure as ours—
i.e. EQ5D, and the data was collected in recent years (in 
2012). Moreover, Mohara’s study had already been used 
for informing policy decisions in Thailand. Since it was 
important to ensure our study’s consistency with the 
parameters used to inform policy decisions, we then 
borrowed data from that study to populate the model. 
It should be noted that the utility data of patients who 
received adjuvant imatinib treatment were collected from 
a small number of patients, because only a few patients 
had access to adjuvant imatinib treatment—it was expen-
sive and could not be reimbursed. Nevertheless, the Thai 
HTA guidelines do not have recommendation on sam-
ple size calculation for health utility data collection. The 
guidelines suggest that the sample size should be as big 
as possible, given the time and resource constraint in 
conducting health economic evaluations. This recom-
mendation is also in line with most other methodological 
guidelines that do not inform about sample size calcula-
tion for utility data measurement.
It was found from the one-way sensitivity analysis that 
the utility of patients who received adjuvant imatinib 
treatment, the probability of recurrence in high risk 
GIST after surgery, and the hazard ratio of recurrence 
in patients who received adjuvant imatinib treatment 
affected the ICER the most. However, this study exten-
sively assessed the variability of these parameters in 
uncertainty analysis –in which we found almost 100% 
chance of making the right recommendation given the 
current ceiling threshold in Thailand. Therefore, pursu-
ing another bigger study would provide no value added to 
policy decision making in Thailand.
Conclusions
Adjuvant imatinib treatment in patients with high risk of 
GIST recurrence after surgery yielded better health out-
comes, yet was not adequate enough to meet the cost-
effective criteria in Thailand compared with no adjuvant 
therapy. The 3-year adjuvant imatinib treatment followed 
by imatinib treatment and best supportive care if recur-
rence occurred after or during adjuvant therapy, respec-
tively, was the best option as it yielded the lowest ICER. 
Therefore, this treatment option should be applied if the 
price of imatinib can be negotiated down to an accept-
able level.
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